Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Warren

Showing results (21-30 of 256) with videos related to

Pageof 26
Sort By:
Molecular Diagnosis & Therapy|April 3, 2010
The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasisCaitriona Ryan, Alan Menter, Richard B Warren
The New England Journal of Medicine|September 15, 2021
Bimekizumab versus Adalimumab in Plaque Psoriasis. ReplyRichard B Warren, Christopher Cioffi, Luke Peterson
Pediatric Dermatology|February 16, 2007
Precalcaneal congenital fibrolipomatous hamartomaRichard B Warren, Julian L Verbov, M Ashworth
Expert Opinion on Biological Therapy|March 12, 2010
The use of ustekinumab in autoimmune diseaseCaitriona Ryan, Breck Thrash, Richard B Warren, et al.
Dermatology and Therapy|March 31, 2016
Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisMolly Campa, Bobbak Mansouri, Richard B Warren, et al.
Expert Opinion on Drug Safety|April 2, 2020
How is safety of dermatology drugs assessed: trials, registries, and spontaneous reportingLeila Asfour, Zenas Z N Yiu, Richard B Warren
Dermatology and Therapy|December 4, 2012
Emerging therapies for the treatment of psoriasisMahir Patel, Antoinette Day, Richard B Warren, et al.
The Journal of Investigative Dermatology|January 27, 2016
One SNP at a Time: Moving beyond GWAS in PsoriasisHelen Ray-Jones, Stephen Eyre, Anne Barton, et al.
Drugs|November 1, 2008
Topical treatments for scalp psoriasisRichard B Warren, Benjamin C Brown, Christopher E M Griffiths
Expert Review of Clinical Immunology|August 13, 2021
Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritisZara Ali, Raymond Matthews, Ali Al-Janabi, et al.
Pageof 26

Showing results (21-30 of 256) with videos related to

Sort By:
Pageof 26
Molecular Diagnosis & Therapy|April 3, 2010
The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasisCaitriona Ryan, Alan Menter, Richard B Warren
The New England Journal of Medicine|September 15, 2021
Bimekizumab versus Adalimumab in Plaque Psoriasis. ReplyRichard B Warren, Christopher Cioffi, Luke Peterson
Pediatric Dermatology|February 16, 2007
Precalcaneal congenital fibrolipomatous hamartomaRichard B Warren, Julian L Verbov, M Ashworth
Expert Opinion on Biological Therapy|March 12, 2010
The use of ustekinumab in autoimmune diseaseCaitriona Ryan, Breck Thrash, Richard B Warren, et al.
Dermatology and Therapy|March 31, 2016
Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisMolly Campa, Bobbak Mansouri, Richard B Warren, et al.
Expert Opinion on Drug Safety|April 2, 2020
How is safety of dermatology drugs assessed: trials, registries, and spontaneous reportingLeila Asfour, Zenas Z N Yiu, Richard B Warren
Dermatology and Therapy|December 4, 2012
Emerging therapies for the treatment of psoriasisMahir Patel, Antoinette Day, Richard B Warren, et al.
The Journal of Investigative Dermatology|January 27, 2016
One SNP at a Time: Moving beyond GWAS in PsoriasisHelen Ray-Jones, Stephen Eyre, Anne Barton, et al.
Drugs|November 1, 2008
Topical treatments for scalp psoriasisRichard B Warren, Benjamin C Brown, Christopher E M Griffiths
Expert Review of Clinical Immunology|August 13, 2021
Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritisZara Ali, Raymond Matthews, Ali Al-Janabi, et al.
Pageof 26